Please use this identifier to cite or link to this item:
Title: OnabotulinumtoxinA in Migraine: A Review of the Literature and Factors Associated with Efficacy.
Austin Authors: Ray, Jason C ;Hutton, Elspeth J;Matharu, Manjit
Affiliation: The National Hospital for Neurology and Neurosurgery, Queen Square, London WC1N 3BG, UK
Department of Neurology, Alfred Hospital, Melbourne, VIC 3004, Australia
Department of Neuroscience, Monash University, Melbourne, VIC 3004, Australia
Headache and Facial Pain Group, University College London (UCL) Queen Square Institute of Neurology, Queen Square, London WC1N 3BG, UK
Issue Date: 29-Jun-2021
Date: 2021-06-29
Publication information: Journal of Clinical Medicine 2021; 10(13): 2898
Abstract: The efficacy of onabotulinumtoxinA (OnaB-A) as a preventative treatment for chronic migraine, emerging fortuitously from clinical observation is now supported by class one evidence and over two decades of real-world clinical data. There is still limited ability to predict a clinically meaningful response to OnaB-A for individual patients, however. This review summarises briefly the proposed mechanism of OnaB-A in chronic migraine, the literature of predictors of clinical response, and recent developments in the field.
DOI: 10.3390/jcm10132898
ORCID: 0000-0003-4833-5507
Journal: Journal of Clinical Medicine
PubMed URL: 34209849
ISSN: 2077-0383
Type: Journal Article
Subjects: botulinum toxin
predictors of efficacy
Appears in Collections:Journal articles

Show full item record

Page view(s)

checked on Dec 10, 2023

Google ScholarTM


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.